Polyneuropathy following vincristine therapy in two patients with Charcot-Marie-Tooth syndrome.
The neurotoxicity of vincristine sulfate, a commonly used antineoplastic agent, has been well described. A literature review failed to reveal any absolute contraindications to the initial use of vincristine. We describe two patients with nodular sclerosing Hodgkin's disease in whom a rapidly progressive, but reversible, severe polyneuropathy developed when they were given a total of 4 mg of vincristine sulfate. Each was later shown to have the demyelinating form of Charcot-Marie-Tooth syndrome. This association suggests that the use of vincristine is contraindicated in patients with the demyelinating form of Charcot-Marie-Tooth syndrome.
D000293:Adolescent; D000328:Adult; D002607:Charcot-Marie-Tooth Disease / Q000150:complications*; D003711:Demyelinating Diseases / Q000150:complications; D005260:Female; D005684:Gait; D006689:Hodgkin Disease / Q000150:complications / Q000188:drug therapy; D006801:Humans; D008297:Male; D009133:Muscular Atrophy / Q000150:complications*; D009431:Neural Conduction / Q000187:drug effects; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D011782:Quadriplegia / Q000139:chemically induced; D014750:Vincristine / Q000009:adverse effects* / Q000627:therapeutic use
D014750:Vincristine